Article Correctness Is Author's Responsibility: Positive Results for Soliris in Neuromyelitis Optica Spectrum Disorder Trial

The article below may contain offensive and/or incorrect content.

In the PREVENT study, the safety and efficacy of Soliris was compared to placebo in patients with AQP4 auto antibody-positive NMOSD (N=143).